

REVIEW

Contemporary evidence on the dynamic role of probiotics in liver diseases

Bilal Ahmed¹, Akhtar Rasul², Kanwal Zia Tareen³, Muhammad Sajid Hamid Akash², Syed Aun Muhammad³, Muhammad Irfan², Khizar Abbas⁴ and Muhammad Imran Qadir^{3*}

¹Department of Clinical Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu Province, China

²Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan

³Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan, Pakistan

⁴Department of Pharmacognosy, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan

Abstract: Currently probiotics are considered as an emerging therapeutic strategy in the treatment of many liver disorders. The use of probiotics beyond infection of intestinal flora is a very helpful approach. The optimistic effect of probiotics has been observed in treating the hepatic cirrhosis, hepatic encephalopathy, viral hepatitis, irritable bowel syndrome, non-alcoholic fatty liver and alcoholic liver disease. The characterize mechanisms of probiotics are still unknown but may involve in, maintaining a microbial barrier against potential pathogens, reducing the production of bacterial toxins, modulating the immune system, intestinal permeability, and the inflammatory response. Its safety issues, effectiveness, food supplements as its source are still to be studied. However, studies revealed that probiotic therapy in hepatocellular carcinoma and in portal hypertension are still weak. Larger clinical studies are required before probiotics can be recommended as a treatment modality in liver diseases.

Keywords: Probiotics, alcoholic liver disease, lactobacilli, bifidobacteria, dietary supplements.

INTRODUCTION

Food and Drug Authority (FDA) accepted the definition of probiotics which was developed by the Food and Agriculture Organization of World Health Organization (WHO) as “live microorganisms which when administered in adequate amounts confer a health benefit on the host” (Venugopalan *et al.*, 2010). Probiotics are seems to be beneficial bacteria which have positive impact on the human beings specially *Lactobacillus* and *Bifidobacterium*. Probiotics are capable to attain the balance of micro flora and decrease the oxidative stress in the gut. Being a natural product, probiotics consider as a new regulatory agent for the regulation of different diseases (Hur and Lee, 2015). Probiotic’s meaning “for life” is demarcated in various techniques. The most current and conventional description of probiotics is “living bacteria that is orally taken in adequate amounts to restore a health benefit on the body” (Merli *et al.*, 2015). In 1953, Kollath devised probiotics as ‘Probiotika’, functional constituents which are important for a healthy growth of life. In 1965, Lilly and Stillwell explained probiotic as a stuff which was formed by one microbe thought-provoking the progression of another microbe (Chen *et al.*, 2015). They believed that a probiotic works as reverse to an antibiotic. In 1974, Parker has a different idea that Probiotics are entities and constituents which subsidize to duodenal microbial balance.

Bacteria in different forms are used as probiotics. Most frequently used microbes are Bifidobacteria and Lactobacilli. These bacteria have mutual association with human. On epithelial cells of the gut these bacteria are mostly present, at this point by producing bactericidal chemicals against these bacteria they stop the progression and attachment of harmful bacteria, Because of its effectiveness and safety of probiotics, these microbe change the typical treatments systems (Quigley, 2015).

Probiotics as dietary enhancements source

We can get the probiotics from the yogurt. Yogurt has fermented milk which changes the lactose into lactic acid. Lactic acid gives the characteristics of yogurt and also denatures and triggers casein, resulting in a semisolid consistency. Bio yogurts are made in a same way, but bacteria used for fermentation are of different strains, usually *L. acidophilus* (Kanuri *et al.*, 2015). Probiotics can also be obtained from fermented and fortified milk and juices. Probiotics can also be approached in the forms of tablets which have dried bacteria, some powders and capsule. The selection of probiotics is depends upon the type of bacteria and the type of benefits. Different strains of probiotics are used on the basis of different results (Federico *et al.*, 2015).

Regulatory guidelines of probiotics

It was typically understood that probiotics are certainly not controlled. However, microbes are used, while probiotics require a mindful safe practices assessment. FDA has

*Corresponding author: e-mail: mrimranqadir@hotmail.com

generated any regulating expert in order to standardize probiotics manufacturing, suppliers, marking along with safe practices regarding products. Of be aware, upon per day May 2007, the FDA given policies that warrant latest GMP with regard to nutritional supplements. While these kinds of policies will not statement authentication regarding skills, they're going to boost the compositional excellent (identity, wholesomeness, along with strength) regarding probiotic products inside market (Sanchez, *et al.*, 2015). Mostly, the FDA does not encounter the actual marking or even safe practices of the probiotic solution with the exception of the place that the solution is talked about to be a medication (i.e. electronic., to deal with, remedy, prevent, offset, or even spot, disease) along with is lacking in approval to be a medication. Food and Drug Authority (FDA) methods upon probiotics count on imagined by using the item (indicated upon Label). Within Food and Drug Authority (FDA) will find four regulating varieties with regard to probiotics along with every one of these features various regulating needs. These are generally (1) Medicine or even scientific items, (2) Health supplements, (3) foods or even foods factor, (4) professional medical foods (Than and Newsome 2015).

If probiotics are generally recommended with regard to make use of medicine, these are generally likewise thought to be scientific items along with Food and Drug Authority (FDA) restrictions regarding scientific items also are put on upon probiotics. If these kind of should be recycled while "nutritive complements", the actual productions may possibly marketplace place this without the pre-approbation. However producer has to enlighten FDA the actual entitlements with the solution. As well as it will be dealt with while "new nutritional ingredient". If it is used as foods or even food's factor, the actual Food and Drug Authority (FDA) only controls the post-market controls relevant to infection. When solution is release while professional medical foods is zero than pre-market approval will likely be essential (Wang *et al.*, 2015).

Within Europe, the actual probiotic facilitated foods just isn't guided through European regulations. However microbial feedstuff extracts are generally put through restrictions, with regards to safe practices examination of those extracts in pets along with humans. Controlled Committee upon Dog Eating routine (SCAN) in Europe features released any "Qualified Understanding regarding Safety" (QPS) concept. As outlined by this particular belief, the actual types that have very long safe practices figures are generally permitted to be advertised with no extensive protection testing (Ferolla *et al.*, 2015).

Probiotics in liver diseases

This liver organ as well as digestive tract has a critical relationship in a way that the blood stream is usually maintained by digestive tract towards the circulatory system. Hard working liver capabilities usually are activated by digestive tract bloodstream content. Also bile

release that is generated by liver organ has an effect on digestive tract performance. It really is begin of which any modification inside usual structure involving digestive tract mini flora change liver organ functionality as well as can bring about initiation as well as development involving liver organ diseases (Zhanga *et al.*, 2015). A lot of problems (Hepatic encephalopathy, cirrhosis, quickly arranged bacteria's peritonitis) usually are linked with overgrowth involving parasites, modified digestive tract absorbency as well as inappropriate immune function. Probiotics are usually hassle-free within dealing with chronic liver organ illnesses while they block entry involving germs to plasma circulation and finally to liver organ via improving the potency of digestive tract obstacle. One more procedure requires the particular legislations involving digestive tract mini flora as well as legislations involving immune capabilities. Most of these additionally diminish the particular extension involving Hepatic encephalopathy as well as support different doctor prescribed pertaining to dealing with Hepatic encephalopathy (Best *et al.*, 2015).

The particular results connected with probiotics about hardworking liver wellbeing ended up observed in a number of studies (Hur and Lee, 2015). The real key mechanisms expressed within these types of reports are the changes within gut characteristics. Ingestion connected with probiotics may make it possible for enterobacteriaceae from the competitive inhibition. Growing nutritional methods, mucosal filter mending, apoptosis prevention as a result of provided that connected with brief archipelago acids, as well as refining digestive tract epithelial sustainability tend to be some other probiotic exclusive outcomes that minimize physical luminal permeability along with lowering ammonia adsorption (Lambert *et al.*, 2015). These kinds of roles lessen tight junction disorder by pathogens, and are also critical means for dropping BT. Generation of anaerobes and gram positive bacteria growth, restraining gram damaging bacteria and preventing pathogens adherents usually are other anti-translocation special effects of the probiotics. Regulatory flora bacteria quantity may result in reduced endotoxins and other toxins resulting from bacteria such seeing that ethanol, phenol, indoles which can damage the liver (Best *et al.*, 2015). Reduced levels of these substances from the liver result in lowering of pro inflammatory production including TNF- α , IL-6 and IFN- γ via down-regulation of the NF- κ B. On the other palm, they can decrease urease activity of micro flora bacteria and then ammonia production and release in the portal system. Moreover, probiotic decreases fecal pH benefit and decreases ammonia adsorption (Kanuril *et al.*, 2015).

Non-alcoholic fatty liver disease (NAFLD)

NAFLD would be the many prevailing hardworking liver ailment internationally. That comes about in every age brackets coming from little ones for you to adults. NAFLD is made up of a big selection regarding diseases

coming from steatosis for you to nonalcoholic steatosis hepatitis (NASH). Frequent histological manifestations including macro vesicular steatosis, hardworking liver cirrhosis, and portal hypertension, along with hepatocellular carcinoma are noticed in NAFLD (Lara *et al.*, 2015). A superior level of lipid hard drive in hepatocytes raises hardworking liver transaminase, along with accretion regarding necro inflammation components are indications of your poor state. NAFLD is associated to diabetes, insulin amount of resistance, along with obesity. Normally, troubles with the metabolic condition are noticed in these individuals. Just lately, two theories are introduced in regards to the signs regarding NASH. The first principle expresses which insulin amount of resistance allows this travelling regarding fatty acids coming from adipose tissues to the liver. Extreme dangerous materials for example microbe LPS, inflammatory inducer materials, along with not like substrates since electricity options (ethanol, short junk acids) as a result of overgrowth regarding gut micro flora are generally known as causal factors. Overproduction regarding ethanol, endotoxin, along with BT phenomena followed by strange expansion regarding gram negative bacteria Pleasure regarding innate amount of resistance from the hardworking liver along with pleasure regarding hepatic oxidative loss cause hardworking liver loss along with cirrhosis (Mcpherson *et al.*, 2015).

Alcoholic liver disease (ALD)

Alcoholic liver disease (ALD) is often a motive of any large step of disease as well as demise worldwide. Alcohol addiction steato hepatitis (ASH) and related serious ALD is noticeable throughout approximately 30% of heavy drinkers. So, some other elements help with this surge of ASH. Implications from various throughout vivo scientific tests does on creatures as well as people mentioned of which endotoxin produced by bacteria moving into this intestinal tracts capabilities being a cofactor. In addition, an increased amount of endotoxin has been seen in the blood of those patients (Lambert *et al.*, 2015). Hyper permeability in the bowel subsequently simply by alcohol consumption use brings about end toxemia, which can be filtrated because of the inflexible functioning liver as well as activates this pro inflammatory means with regard to producing ASH. In addition, this leakiness of belly invokes NF-kB transcribing as well as over expression of nitric oxide functionality (Razmpoosh *et al.*, 2015). Enhanced functionality of absolutely no leads to oxidative tension throughout hepatocytes. Alcoholic beverages use improves this increase of gram adverse bacteria as well as will increase the number of bifidobacteria as well as lactobacilli (Wieland *et al.*, 2015).

Cirrhosis

Cirrhosis a new vascular illness is approved by simply aspects for instance web site hypertension, in addition to

hyper dynamic syndrome. Similar to utmost liver diseases, lacking security within digestive tract normal-flora, in addition to damage in the colon hurdle lead to end toxemia, a higher degree of pro inflammatory cytokines, with no activity induction (Eamonn *et al.*, 2015). Overgrowth associated with digestive tract micro flora, BT, in addition to end toxemia seen in individuals along with cirrhosis suffered the application of vascular shunts. Most of these difficulties are usually escorted along with arousal associated with swelling in addition to oxidative damage within liver which usually leads to hepatocytes injuries (Lara *et al.*, 2015).

1) Probiotics in compensated cirrhosis

Tandon *et al.* (2009) observed the usefulness of probiotics in patients with compensated cirrhosis. However, Pereg *et al.*, (2011) did not find any significant beneficial effect of probiotics in patients with compensated liver cirrhosis. They used small number of patients in the study and recommended for further investigation on large scale. In a study by Jayakumar *et al.* (2013), probiotic administration supported the beneficial effects of probiotic in patients with compensated cirrhosis.

2) Probiotics in decompensated cirrhosis

Rincon *et al.* (2014) did not find any positive results for use of probiotics in decompensated cirrhosis. Dhiman *et al.* (2014) in a study of six month duration were able to document decrease in plasma levels of TNF- α , IL1 β , IL-6 as well as levels of plasma renin and brain natriuretic peptide after 24 days of probiotics administration in the patients with decompensated cirrhosis. Marlicz *et al.*, (2016) observed improved hepatic and systemic haemodynamics in patients with decompensated cirrhosis after supplementation with probiotics.

Hepatic encephalopathy (HE)

Hepatic Encephalopathy damaging side effects produce extreme and also long term hardworking liver sickness which usually takes place within at the very least 50% to 70 percent involving sufferers together with cirrhosis. That is an extreme supplementary neuropsychiatric sickness which usually appears as a result of variable factors. Production involving ammonia because of the stomach bacteria and its particular generate towards the portal method are identified as central features to dislocate this central neural method, and also bring about hepatic encephalopathy (Zhanga *et al.*, 2015).

Viral hepatitis

Several viruses like hepatitis C and B malware (HCV and HBV) are recognized as causative agents leading to long term hepatocellular injury. High rate these viruses was identified in Iranian population. The plasma a higher level endotoxin increases in patients with HBV along with HCV. Moreover, high degrees of the pro inflammatory cytokines termed beyond plus the necrosis reported in




Fig. 1: Liver diseases treated by probiotics

these patients trigger liver injury inside extensive period. Consequences from lactitol study have an influence on extent regarding endotoxin in people with HCV along with HBV blood, indicated how the mitigation of endotoxemia might be attained by improving lactobacillus and bifidobacteria amounts and circumventing the particular development of bacteria or virus (Wang *et al.*, 2015).

Irritable bowel syndrome (IBS)

IBS includes a spread of symptoms, like belly pain, altered internal organ habits, bloating and flatulence within the absence of structural abnormalities within the intestine. As no curative treatment are often found for IBS, medical aid is palliative and certificatory, aimed towards special symptoms, and is notoriously unsatisfactory. Studies have ascertained alterations in internal organ micro flora in patients and augmented signs or symptoms following enteric infections, so probiotics might probably be a useful gizmo to spice up symptoms (Merli *et al.*, 2015). Probiotic treatment possesses the potential to decrease the actual severity of symptoms in IBD via interaction together with gut epithelium. Planned mechanisms embrace changes merely speaking chain fatty acids (SCFA) production patterns, reduction in pro-inflammatory protein unleash, up Th1/Th2 ratios, together with eliminating pathogens (Quigley, 2015).

Probiotics in liver transplantation

There is more chance of death within the three months after liver transplantation due to bacterial infections. Probiotics have been proved to decrease the incidence of bacterial infections in patients with liver transplantation. Probiotics have also been useful for decreasing the duration of antibiotic therapy in patients with liver

transplantation. In contrast to antibiotics, probiotics are comparatively low-priced and does not cause severe adverse effects (Zhang *et al.*, 2013).

FUTURE PERSPECTIVES

The problem of resistance and tolerance to the existing drugs has created a decreased efficacy of these drugs. This problem has been tried to be overcome by the use of polymers (Khalid *et al.*, 2009; Hussain *et al.*, 2011; Irfan *et al.*, 2016a; Irfan *et al.*, 2016b; Qadir, 2017) or through nanotechnology (Naz *et al.*, 2012; Ehsan *et al.*, 2012), synthesis of new drugs, either by the use of proteomics (Qadir, 2011), or synthesis from lactic acid bacteria (Masood *et al.*, 2011), or marine microorganisms (Javed *et al.*, 2011). However, now-a-days, the trend is also being changed to the use of natural products. Large numbers of natural constituents are constantly being screened for their possible pharmacological value particularly for their analgesic (Hussain *et al.*, 2017a & b), anti-inflammatory (Qadir, 2009), hypotensive (Qadir, 2010; Qadir *al.*, 2018), hepatoprotective (Ahmad *et al.*, 2012; Qadir and Ahmad, 2017), hypoglycaemic (Qadir and Ahmed, 2017) amoebicidal, anti-aging (Qadir and Anwar, 2017), cytotoxic, antibiotic (Amin *et al.*, 2012; Mannan *al.*, 2016; Qadir *al.*, 2016; Qadir and Sajjad, 2017; Qadir *al.*, 2018), antibacterial (Qadir and Chuahday, 2018; Qadir and Mobeen, 2018), spasmolytic, bronchodilator, antioxidant (Janbaz *et al.*, 2012), antiviral (Qadir and Abid, 2017; Qadir and Zafar, 2017; Qadir, 2018a) and anti-cancer properties (Qadir, 2016; Qadir, 2017; Bashir and Qadir, 2017; Qadir and Cheema, 2017; Qadir and Faheem, 2017; Qadir and Rizvi, 2017; Qadir, 2018b). Probiotics may prove strong candidates for management of liver diseases in near future.

CONCLUSION

Probiotic treatment method demonstrates zero significant side effects disparate antibiotic remedy. While consequences from clinical demos carried out about common liver organ conditions discovered constructive unique consequences of probiotics. There may be emergent identification in which change of instinct micro biota features has a causative effect on our pathogenesis of numerous liver organ disorders together with troubles of liver organ cirrhosis. Nonetheless, function of probiotics in this particular perspective remains controversial. Establishing files are usually motivating primarily in the field of hepatic encephalopathy in addition to NASH, though advance scientific studies are important before probiotics may be contained in the pertinent treatment method algorithms.

REFERENCES

- Bashir MF and Qadir MI (2017) Effect of ginger extract on angiogenesis using CAM assay. *Bangladesh J. Pharmacol.*, **12**(3): 348-353.
- Best NV, Jansen PL and Rensen SS (2015). The gut microbiota of nonalcoholic fatty liver disease: Current methods and their interpretation. *Hepatol. Int.*, **9**(3): 406-415.
- Chen P, Torralba M, Tan J, Embree M, Zengler K, Starkel P, Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE and Fouts DE (2015). Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. *Gastroenterology*, **148**(1): 203-214.
- Dhiman RK, Rana B and Agrawal S *et al* (2014). Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: A randomized, controlled trial. *Gastroenterology*, **147**(6): 1327-1337.
- Eamonn MM Quigley (2015). Is the gut microbiota disturbed in chronic liver disease? *Clinical Liver Disease*, **5**(4): 94-95.
- Federico A, Dallio M, Godos J, Loguercio C and Salomonec F (2016). Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. *Transl. Res.*, **167**(1): 116-124.
- Ferolla S, M Armiliato GN, Couto CA and Ferrari TCA (2015) Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. *World J. Hepatol.*, **7**(3): 559-565.
- Hur KY and Lee MS (2015). Gut microbiota and metabolic disorders. *Diabetes & Metabol. J.*, **39**(3): 198-203.
- Hussain L, Abbas K, Ahmed B, Baber M, Muhammad SA and Qadir MI (2017a) Analgesic and anti-inflammatory activity of aqueous-methanolic extract of *Aerva javanica*. *Pak. J. Pharm. Sci.*, **30**(1): 213-215.
- Hussain L, Ain NU, Akash MSH, Iqbal R, Irfan M and Qadir MI (2017b) Analgesic, anti-inflammatory and antipyretic activity of *Salvia moorcroftiana*. *Pak. J. Pharm. Sci.*, **30**(2): 481-486.
- Irfan M, Akram A, Zahoor AF, Qadir MI, Hussain A, Abbas N, Khan A, Arshad MS and Khan NI (2016a) Formulation parameters affecting floating behaviour and drug release from extended release floating tablets of ranitidine hydrochloride. *Lat. Am. J. Pharm.*, **35**(Suppl. 1): 1206-16.
- Irfan M, Rabel S, Bukhtar Q, Qadir MI, Jabeen F and Khan A (2016b) Orally disintegrating films: A modern expansion in drug delivery system. *Saudi Pharma. J.*, **24**(5): 537-546.
- Jayakumar S, Carbonneau M and Hotte N (2013). VSL#3 probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis. *Liver Int.*, **33**(10): 1470-1477.
- Kanuril G, Ladurner R, Skibovskaya J, Spruss A, Konigsrainer A, Bischoff SC and Bergheim I (2015). Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. *Liver Int.*, **35**(2): 562-568.
- Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL and Reimer RA (2015) Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: A randomized controlled trial protocol. *BMC Gastroenterol.*, **15**: 169.
- Lara MJS, Lorente CG, Diaz JP and Gil A (2015). The Role of Probiotic Lactic Acid Bacteria and Bifidobacteria in the Prevention and Treatment of Inflammatory Bowel Disease and Other Related Diseases: A Systematic Review of Randomized Human Clinical Trials. *BioMed Res. Int.*, **125**(2): 134-147.
- Mannan M, Hussain L, Ijaz H and Qadir MI (2016) Antimicrobial activity of *Kalanchoe laciniata*. *Pak. J. Pharm. Sci.*, **29**(4): 1321-1324.
- Marlicz W, Wunsch E, Mydlowska M, Milkiewicz M, Serwin K, Mularczyk M, Milkiewicz P and Raszewicz-Wyszomirska J (2016). The effect of short term treatment with probiotic VSL#3 on various clinical and biochemical parameters in patients with liver cirrhosis. *J. Physiol. Pharmacol.*, **67**(6): 867-877.
- McPherson S, Anstee QM and Dyson JK (2015) Non-alcoholic fatty liver disease: A practical approach to treatment. *Postgrad. Med. J.*, **91**(1072): 92-101.
- Merli M, Lucidi C, Gregorio VD, Giannelli V, Giusto M, Ceccarelli G, Riggio O and Venditti M (2014). The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. *Liver Int.*, **35**(2): 362-369.
- Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M and Kitay-Cohen Y (2011) Probiotics for patients with compensated liver cirrhosis: A double-blind placebo-controlled study. *Nutrition*, **27**(2): 177-81.

- Qadir MI (2016) Skin cancer: etiology and management. *Pak. J. Pharm. Sci.*, **29**(3): 999-1003.
- Qadir MI (2017) Nanopreparations for better drug delivery. *Pak. J. Pharm. Sci.*, **30**(6): 2301-2309.
- Qadir MI (2017) Role of green tea flavonoids and related constituents in cancer prevention. *Crit. Rev. Eukaryot. Gene Expr.*, **27**(2): 163-171.
- Qadir MI (2018a) Hepatitis in AIDS Patients. *Rev. Med. Virol.*, **28**:e1956
- Qadir MI (2018b) Qadir theory of cancer etiology. *Crit. Rev. Eukaryot Gene Expr.* **28**(1):13-15.
- Qadir MI and Abid A (2017) Acute HIV infection: advances in mechanism and prophylactic therapeutic management. *Crit. Rev. Eukaryot. Gene Expr.*, **27**(1): 79-90.
- Qadir MI and Ahmad Z (2017) Advances in hepatoprotective medicinal plants research. *Bangladesh J. Pharmacol.*, **12**(3): 229-242.
- Qadir MI and Ahmed Z (2017). *Lep* expression: Role in obesity and diabetes type 2. *Crit. Rev. Eukaryot. Gene Expr.*, **27**(1): 47-51.
- Qadir MI and Anwar S (2017) Sirtuins in brain aging and neurological disorders. *Crit. Rev. Eukaryot. Gene Expr.*, **27**(4): 321-329.
- Qadir MI and Cheema BN (2017) Phytoestrogens and related food components in prevention of cancer. *Crit. Rev. Eukaryot. Gene Expr.*, **27**(2): 99-112.
- Qadir MI and Chuahday Z (2018) Antibacterial activity of novel strains of bacteriophages: An experimental approach. *Crit. Rev. Eukaryot. Gene Expr.*, **28**(1):1-12.
- Qadir MI and Faheem A (2017) miRNA: A diagnostic and therapeutic tool for pancreatic cancer. *Crit. Rev. Eukaryot. Gene Expr.*, **27**(3): 197-204.
- Qadir MI and Mobeen T (2018) Phage therapy: Progress in pharmacokinetics. *Braz. J. Pharm. Sci.*, **54**(1): e17093.
- Qadir MI and Rizvi SZ (2017) miRNA in hepatocellular carcinoma: Pathogenesis and therapeutic approaches. *Crit. Rev. Eukaryot. Gene Expr.*, **27**(4): 355-361.
- Qadir MI and Sajjad S (2017) Phage therapy against *Streptococcus pneumoniae*: Modern tool to control pneumonia. *Crit. Rev. Eukaryot. Gene Expr.*, **27**(4): 289-295.
- Qadir MI and Zafar M (2017) TSG101: Tumor susceptibility gene 101 (tsg101) product - Role in therapy against HIV/AIDS. *Crit. Rev. Eukaryot. Gene Expr.*, **27**(3): 237-246.
- Qadir MI, Abbas K, Younus A and Shaikh RS (2016) Antibacterial activity of sea buckthorn (*Hippophae rhamnoides* L.) against methicillin resistant *Staphylococcus aureus* (MRSA). *Pak. J. Pharm. Sci.*, **29**(5): 1705-1707.
- Qadir MI, Hasan I and Mobeen T (2018) *In-silico* study of potential carboxylic acid derivatives as D-glutamate ligase inhibitors in *Salmonella typhi*. *Kuwait J. Sci.* **45**(1): 100-107.
- Qadir MI, Manzoor A and Akash MSH (2018) Potential role of medicinal plants for anti-atherosclerosis activity. *Bangladesh J. Pharmacol.*, **13**(1): 59-66.
- Quigley EM (2015). Is the gut microbiota disturbed in chronic liver disease? *Clinical Liver Disease*, **5**(4): 94-95.
- Razmpoosh E, Ejtahed HS, Mirmiran P and Javadi M (2015). Role of probiotics in Glycemic Controls and Body Weight in Type 2 Diabetes: A Systematic of Human and Animal Studies. *IJEM*, **17**(1): 63-87.
- Rincon D, Vaquero J and Hernando A *et al* (2014). Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. *Liver Int.*, **34** (10): 1504-1512.
- Sanchez E, Nieto JC, Boullosa A, Vidal S, Sancho FJ, Rossi G, Sancho-Bru P, Oms R, Mirelis B, Juarez C, Guarner C and Soriano G (2015). Probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. *Liver Int.*, **35**(3): 735-745.
- Sánchez E, Nieto JC, Boullosa A, Vidal S, Sancho FJ, Rossi G, Bru PS, Oms R, Mirelis B, Juarez C, Guarner C and Soriano G (2015). VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. *Liver Int.*, **35**(3): 735-745.
- Tandon P, Moncrief K and Madsen K (2009). Effects of probiotic therapy on portal pressure in patients with cirrhosis: A pilot study. *Liver Int.*, **29**(7): 1110-1115.
- Than NN and Newsome PN (2015). A concise review of non-alcoholic fatty liver disease. *Atherosclerosis*, **239**(1): 192-202.
- Venugopalan V, Shriner KA and Wong-Beringer A (2010). Regulatory Oversight and Safety of Probiotic Use. *Emerging Infec. Dis.*, **16**(11): 1661-1665.
- Wang J, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, Strisse K, Zhao L, Obin M and Shen J (2015). Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. *The ISME Journal*, **9**(1): 1-15.
- Wieland A, Frank DN, Harnk B and Bambha K (2015). Systematic review: Microbial dysbiosis and nonalcoholic fatty liver disease. *Alimentary Pharmacol. & Therap.*, **42**(9): 1051-1063.
- Zhang Y, Chen J, Wu J, Chalson H, Merigan L and Mitchell A (2013). Probiotic use in preventing postoperative infection in liver transplant patients. *Hepatobiliary Surg. Nutr.*, **2**(3): 142-147.
- Zhanga M, Wang C, Wang C, Zhao C, Zhao C, Chend Y, Wang Y, McClain C and Feng W (2015). Enhanced AMPK phosphorylation contributes to the beneficial effects of *Lactobacillus rhamnosus* GG supernatant on chronic-alcohol-induced fatty liver disease. *J. Nutr. Biochem.*, **26**(4): 337-344.